{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:31:34Z","timestamp":1791469894792,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ygyno.2021.02.030","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T14:53:11Z","timestamp":1615560791000},"page":"621-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma"],"prefix":"10.1016","volume":"161","author":[{"given":"Antonio","family":"Raffone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Travaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Boccellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Maletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Borghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Casadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Insabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Seracchioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2021.02.030_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.030_bb0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.030_bb0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.02.030_bb0020","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s12253-020-00829-9","article-title":"TCGA classification of endometrial cancer: the place of carcinosarcoma","volume":"26","author":"Travaglino","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.030_bb0025","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00404-020-05542-1","article-title":"Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups","volume":"301","author":"Travaglino","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.030_bb0030","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00404-020-05531-4","article-title":"TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma","volume":"301","author":"Travaglino","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.030_bb0035","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2020.01.008","article-title":"Histopathological characterisation of ProMisE molecular groups of endometrial cancer","volume":"157","author":"Raffone","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.030_bb0040","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s12253-019-00784-0","article-title":"TCGA molecular subgroups in endometrial undifferentiated\/dedifferentiated carcinoma","volume":"26","author":"Travaglino","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.030_bb0045","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/his.13976","article-title":"Clear cell endometrial carcinoma and the TCGA classification","volume":"76","author":"Travaglino","year":"2020","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.030_bb0050","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"issue":"9","key":"10.1016\/j.ygyno.2021.02.030_bb0055","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/PAS.0b013e31828c63ed","article-title":"Histotype-genotype correlation in 36 high-grade endometrial carcinomas","volume":"37","author":"Hoang","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.030_bb0060","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.030_bb0065","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2021.02.030_bb0070","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.030_bb0075","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"issue":"7447","key":"10.1016\/j.ygyno.2021.02.030_bb0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterisation of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.030_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/aogs.13716","article-title":"BAG3 expression correlates with the grade of dysplasia in squamous intraepithelial lesions of the uterine cervix","volume":"99","author":"Raffone","year":"2020","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"11","key":"10.1016\/j.ygyno.2021.02.030_bb0090","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/apm.12988","article-title":"Nuclear expression of \u03b2-catenin in endometrial hyperplasia as marker of premalignancy","volume":"127","author":"Travaglino","year":"2019","journal-title":"APMIS"},{"issue":"9","key":"10.1016\/j.ygyno.2021.02.030_bb0095","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/apm.12977","article-title":"Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer","volume":"127","author":"Raffone","year":"2019","journal-title":"APMIS"},{"issue":"9","key":"10.1016\/j.ygyno.2021.02.030_bb0100","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.030_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1264565","article-title":"Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition","volume":"6","author":"Eggink","year":"2016","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.030_bb0110","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2016.11.023","article-title":"Polymerase \u03b5 (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro","volume":"144","author":"Bellone","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.030_bb0115","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/his.13338","article-title":"Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf\u2019s clothing","volume":"72","author":"Van Gool","year":"2018","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.030_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"PRISMA-P group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.030_bb0125","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/uog.15762","article-title":"Synthesizing evidence from diagnostic accuracy tests: the SEDATE guideline","volume":"47","author":"Sotiriadis","year":"2016","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.02.030_bb0130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.030_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.030_bb0140","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1172\/JCI84940","article-title":"Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer","volume":"126","author":"Mehnert","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.030_bb0145","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/PAS.0000000000001395","article-title":"PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups","volume":"44","author":"Pasanen","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.02.030_bb0150","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.030_bb0155","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.5081","article-title":"Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response","volume":"245","author":"Temko","year":"2018","journal-title":"J. Pathol."},{"issue":"14","key":"10.1016\/j.ygyno.2021.02.030_bb0160","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE proofreading mutations elicit an antitumor immune response in endometrial cancer","volume":"21","author":"Van Gool","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.ygyno.2021.02.030_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153025","article-title":"Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer","volume":"216","author":"Raffone","year":"2020","journal-title":"Pathol. Res. Pract."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.030_bb0170","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s12253-020-00811-5","article-title":"Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer","volume":"26","author":"Raffone","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.030_bb0175","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.030_bb0180","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.030_bb0185","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/PAS.0000000000001461","article-title":"Endometrial carcinomas with a \u201cSerous\u201d component in young women are enriched for DNA mismatch repair deficiency, lynch syndrome, and POLE exonuclease domain mutations","volume":"44","author":"Conlon","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.030_bb0190","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Pathol."},{"issue":"17","key":"10.1016\/j.ygyno.2021.02.030_bb0195","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1016\/j.ejca.2005.07.017","article-title":"Inflammation and prognosis in colorectal cancer","volume":"41","author":"Klintrup","year":"2005","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.030_bb0200","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582100175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582100175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:47:55Z","timestamp":1715820475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582100175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S009082582100175X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.02.030","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}